AlphAIAlphAI — Financial news for AI agents
investing.comOCT 202 min read$MYGN

TD Cowen holds Myriad Genetics stock rating on Labcorp sale

TD Cowen reiterated a Hold rating and $4.50 price target on Myriad Genetics (MYGN) after it agreed to sell its Prenatal Health business to Labcorp for $210M. MYGN shares trade at $5.76, with a market cap of $550M. The sale aims to simplify the company's portfolio and focus on Cancer Care Continuum. MYGN reported Q2 2026 revenue of $190.7M, down 11% YoY, missing estimates. Piper Sandler downgraded MYGN to Underweight with a $2 price target.

Original reporting
investing.com
Published Oct 20, 2026, 5:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 5:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$MYGN
Bearish
high confidence
Mentioned
$MYGN · $LH
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MYGNBearishMed
01

Why it matters

The combination of a sizable divestiture and a sharp downgrade creates a mixed signal; short‑term price pressure is likely, but the cash infusion could support future growth in core cancer diagnostics.

02

Market read

The news directly impacts MYGN's valuation and may influence peer biotech stocks.

03

What to watch

Potential tax benefits and strategic focus on higher‑margin cancer diagnostics may improve long‑term earnings.

Relevance 7/10Novelty 7/10Timing: today

Background

Myriad Genetics (MYGN) disclosed a $210M sale of its Prenatal Health business to Labcorp and faced a downgrade from Piper Sandler, while TD Cowen maintained a Hold rating.

Company-level read

Ticker impact

$MYGNBearishHigh confidence
Context

TD Cowen reiterated Hold and $4.50 target after Myriad Genetics announced a $210M cash sale of its Prenatal Health business to Labcorp and Piper Sandler downgraded the stock to Underweight with a $2.00 target.

Expected impact

likely pressure as the market prices in the downgrade and concerns over profitability

Evidence & confidence

A fresh $210M asset sale is material for a $550M market‑cap company, and the downgrade cuts the price target by more than half, indicating traders may sell on the news.

Market effects

Sector

Health‑genomics firms may face heightened scrutiny on profitability as Myriad sheds a prenatal unit.

Regional

U.S. biotech sector could see modest pullback amid analyst downgrades.

Global

Limited to investors tracking specialty genetics and lab services.

Counterpoint

What could challenge this read

The cash proceeds could fund growth in the cancer portfolio, offering upside if the market overreacts to the downgrade.

Key entities

  • company
    Myriad Genetics

    Genomics company selling its prenatal unit.

  • company
    Labcorp

    Buyer of Myriad's Prenatal Health business.

  • analyst_firm
    TD Cowen

    Maintained Hold rating on MYGN.

  • analyst_firm
    Piper Sandler

    Downgraded MYGN to Underweight.

Read at source← All news

StoryMyriad Genetics to sell its Prenatal Health unit to Labcorp for $210 million in cash

Also covered by

5 outlets

Related articles

OCT 20
$MYGNHighAI 9/10

Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing Business

Myriad Genetics (MYGN) shares rose 36.94% to $5.77 on news of selling its Prenatal Health testing business to Labcorp (LH) for $210M in cash. The deal, expected to close in early 2027, is projected to boost MYGN's revenue growth and profitability, according to the company. Labcorp anticipates $160M in revenue from the acquisition in its first year.

investorideas.com2 min
OCT 20
$QGENMed

Qiagen Deal Chatter Lifted US Healthcare Stocks

EQT offered $50+ per share for Qiagen, raising its stock 5.8%. Labcorp agreed to buy Myriad Genetics' prenatal testing unit for $210M, boosting Myriad 36% and Labcorp 1%. GeneDx gained on sequencing plans. Investors focus on deal probabilities and sector-wide M&A expectations.

finimize.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics stock surges on $210M prenatal unit sale

Myriad Genetics (MYGN) shares rose 36% after announcing a $210M sale of its prenatal testing unit to Labcorp (LH). The deal includes tests generating $160M in annual revenue. Myriad expects the sale to boost growth and profitability, while Labcorp anticipates added revenue and slight earnings accretion. The transaction is expected to close by early 2027, pending regulatory approval.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

Myriad Genetics (MYGN) shares rose 22.2% premarket after agreeing to sell its Prenatal Health business to Labcorp for $210M in cash plus inventory. The deal, expected to close by early 2027, includes a $10.5M reverse termination fee. The prenatal division had seen a 16% YoY revenue decline in Q2. CEO Sam Raha stated the divestiture will improve overall revenue growth and profitability.

financialcontent.com2 min
OCT 20
$MYGNHighAI 8/10

Myriad Genetics (MYGN) Shares Surge 20% Premarket on Prenatal He

Myriad Genetics (MYGN) shares rose 20% premarket after announcing the sale of its Prenatal Health division to Labcorp for $210M. Labcorp expects $160M in first-year revenue from the acquisition. MYGN's P/S ratio is 0.49, below historical and industry averages, reflecting market skepticism about growth. The company's GF Score is 47, indicating moderate financial health with weak growth and profitability.

gurufocus.com2 min
OCT 20
$LHMedAI 8/10

Labcorp To Buy Myriad Genetics' Prenatal Testing Business For $210 Mln

LabCorp (LH) will acquire Myriad Genetics' (MYGN) prenatal testing business for $210M in cash plus inventory value. The deal includes products like Prequel and Foresight. LabCorp expects $160M in revenue the first year and slight earnings accretion. Myriad plans to invest proceeds in cancer care. The transaction is expected to close by early 2027.

rttnews.com2 min